Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma

• Status: Not yet recruiting
• Trial end date: 2025-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongnan Hospital
• Treatments: Etoposide

Criteria

Inclusion Criteria:

• Age between 18 and 70,

• performance status of 0-1 (Eastern Cooperative Oncology Group performance status),

• histologically confirmed MGMT gene promoter unmethylation glioblastoma

• no cerebrospinal fluid and distant metastatic disease.

• adequate hematologic, hepatic, and renal function

Exclusion Criteria:

• younger than 18 years;

• with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities